InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（10 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
10
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Oliviero James F III, 董事长兼首席执行官. Insider active across 2 companies, notably Checkpoint Therapeutics, Inc.. Aggregated, 20 reports have been logged. Split: 0 buy · 10 sells. Total volume traded: €2.7m. History available since 31 January 2022. The latest transaction was filed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Oliviero James F III
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
30,000 股0Common StockSEC:0001104659-25-058916:0
3,759,929 股COMMON STOCKSEC:0001104659-25-054690:0
15,090 股@ US$4.041.6% 占其流量COMMON STOCKSEC:0001104659-25-031813:0
9,233 股@ US$3.410.9% 占其流量COMMON STOCKSEC:0001104659-25-011656:0
1,500,000 股0COMMON STOCK (RESTRICTED)SEC:0001104659-25-008258:0
602,167 股@ US$3.8762.6% 占其流量COMMON STOCKSEC:0001104659-24-130963:0
2,077,700 股0COMMON STOCKSEC:0001104659-24-129525:0
24,610 股@ US$2.051.3% 占其流量COMMON STOCKSEC:0001104659-24-076442:0
30,000 股0Common StockSEC:0001104659-24-071284:0
1,660,000 股0COMMON STOCK (RESTRICTED)SEC:0001104659-24-065214:0
5,894 股@ US$2.060.3% 占其流量COMMON STOCKSEC:0001104659-24-030149:0
11,900 股@ US$2.010.6% 占其流量COMMON STOCKSEC:0001104659-24-010265:0
18,000 股0Common StockSEC:0001104659-23-072607:0
250,000 股0COMMON STOCK (RESTRICTED)SEC:0001104659-23-041761:0
5,548 股@ US$4.650.7% 占其流量COMMON STOCKSEC:0001104659-23-028603:0
10,261 股@ US$4.771.3% 占其流量COMMON STOCKSEC:0001104659-23-010771:0
3,817 股@ US$6.7490.7% 占其流量COMMON STOCKSEC:0001104659-23-003529:0
228,000 股@ US$1.0922.1% 占其流量COMMON STOCKSEC:0001104659-22-076976:0
302,777 股@ US$3.1123.4% 占其流量COMMON STOCKSEC:0001104659-22-049156:0
455,000 股0COMMON STOCK (RESTRICTED)SEC:0001104659-22-010997:0
20 条申报中的 20 条
About Oliviero James F III
Oliviero James F III is Président-Directeur Général and has 20 filings in total. Across the 20 sampled filings between 2022-02-02 and 2025-06-12, the modal transaction nature is Cession, with 0 in buys and 2716378 in euro sells, mainly in Checkpoint Therapeutics, Inc. He is also listed as CEO, President and Director of Checkpoint Therapeutics, Inc. and Director of Nuvectis Pharma, Inc.
